Abstract: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function of each group. Once bound to the surface, via the latent reactive group, the reagent presents the aliphatic acid to the physiological environment, in vivo, in a manner (e.g., concentration and orientation) sufficient to hold and orient albumin.

Abstract: Hydrogel biomedical articles formed from macromers having a polymeric backbone comprising 1,2-diol and/or 1,3-diol units, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and, optionally, other modifiers.

Abstract: Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably ?-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

Abstract: A premix parenteral solution for intravenous administration having amiodarone, as an active ingredient, solubilized in a solution of water for injection and about 0.4-12 mg/ml of a non-ionic surfactant to a concentration range of from 0.2 to 6 mg/ml is disclosed. The solution optionally may include an osmotic agent. No dilution of the solution is required before administering to a patient and the sterile packaged solution has an initial pH within the range of from about 2.9 to about 3.2, preferably about 3.1. Additionally, a method for producing an amiodarone solution suitable for intravenous administration is further disclosed.

Abstract: The present invention concerns a novel sustained-release oral formulation of morphine sulphate in the form of microgranules. Each microgranule comprises a neutral support grain coated with an active layer and with a sustained-release layer, characterized in that the sustained-release layer contains a copolymer of methacrylic acid and of methyl methacrylate ester, the relative proportion of the free carboxyl groups and of the ester groups of which is equal to 0.5 approximately, and a silica exhibiting a hydrophobic character. The present invention also concerns a process for preparing these microgranules which is carried out entirely in aqueous medium by emplacing on neutral support grains.

Abstract: A transdermal drug delivery device for topical application of active agents is disclosed. The invention comprises the use of a flexible and soft backing layer, in particular a cellular foam, having an inner surface and an outer surface, wherein an impermeable polymeric barrier film is affixed to its inner surface. The barrier film functions to anchor and support an active agent carrier composition disposed thereon, and to prevent passage of such composition into the backing layer. The system provides excellent flexibility and conformability for topical application to sites subject to frequent movement or which are greatly contoured. Methods of use are also disclosed.

Abstract: The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs.

Abstract: The present invention relates to a substantially ammonia free hair bleach product. Specifically, the invention concerns hair bleach products that comprise a hydrogen peroxide developer; a powder activator containing a mixed persulfate oxidizing system, and a monoethanolamine alkalizing agent.

Abstract: A patch comprising an adhesive layer formed on one surface of a flexible support, wherein said adhesive layer containing a drug, an absorption enhancer and an adhesive comprising; (i) said drug is buprenorphine hydrochloride and/or buprenorphine, and (ii) said absorption enhancer is a mixture of polyoxyethylene sorbitan mono fatty acid ester having 6 to 20 of oxyethylene units and 12 to 18 of carbon number of fatty acid ester, and at least one selected from the group consisting of liquid higher fatty acid ester, 60 to 180 of molecular weight of liquid poly hydric alcohol, lactic acid and triacetin, and (iii) said adhesive is an acrylic-based adhesive.

Abstract: The present invention relates to a solid composition useful for tissue gluing, tissue sealing and hemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the range of 5-100 N/cm, density of 1-10 mg/cm3, chamber diameter of more than 0.75 mm and less than 4 mm and/or having a chamber diameter average below 3 mm and evenly distributed and fixed upon said carrier, b) solid fibrinogen, and c) solid thrombin. The carrier is a biodegradable polymer such as a polyhyaluronic acid, polyhydroxy acid, e.g. lactic acid, glucolic acid, hydroxybutanoic acid, a cellulose, gelatine or collagen, such as a collagen sponge, e.g. a collagen sponge consisting essentially of collagen type I fibers. The fibrinogen and thrombin are preferably human, purified from a natural source, or transgenic or recombinant human fibrinogen and/or thrombin.

Abstract: The instant invention is directed toward a dermal delivery system composition comprising an aqueous base vehicle including American Emu oil, Isopropyl Palmitate (PROTACHEM IPP), PEG-8 (a polyethylene glycol available under the tradename PROTACHEM 400), methylsulfonylmethane (MSM) and SEPIGEL 305 (a combination including polyacrylamide/C13–C14 Iso-paraffin and Laureth-7), in combination with an analgesic composition, such as ibuprofen, and to processes for the manufacture and use thereof.

Abstract: The present invention is directed to a sustained release pharmaceutical composition in oral dosage form consisting essentially of a pharmaceutically effective amount of a medicament and a hydrophobic material in the absence of a lactose or hydrophobic carbohydrate polymer, said medicament being present in an amount greater than about 25% of the pharmaceutical composition and having a water solubility greater than about 1 gram per 10 mL of water at 25° C., said hydrophobic material having a melting point ranging from at least about 40° C. to about 100° C. at 1 atm pressure, and being present in an amount ranging from about 3% to about 20% by weight of the pharmaceutical composition and in an amount less than the of the medicament, and said hydrophobic material not being present in coating of said pharmaceutical composition; said pharmaceutical composition being prepared by direct compression in the absence of or melting the hydrophobic material or the use of high shear mixer.

Abstract: The present invention is to provide a metal oxide.organopolysiloxane hybrid powder, wherein a silicon atom of organopolysiloxane is bonded by covalent bond with a metal atom through an oxygen atom and complicated homogeneously. Titanium and/or zirconium is desirably used as the above mentioned metal atom. Especially, a porous titanium oxide.organopolysiloxane hybrid powder whose specific surface area is larger than 50 m2/g is desirably used. Said hybrid powder can be produced by generating sol by hydrolysis of metal alkoxide, adding reactive organopolysiloxane to said sol to generate hybrid sol solution, then precipitating it. The method to produce titanium oxide.silica composite by the heat treatment of porous titanium oxide.organopolysiloxane hybrid powder can be also mentioned. By making hybrid, the optical properties of metal oxide powder can be controlled and dispersing ability, dispersing stability, water repellency and hard feeling can be improved.

Abstract: Improved extrusion-processed daily ration animal feeds are provided which include minor amounts of actives to ensure that an animal consuming the feed receives quantities of the actives sufficient to establish and maintain substantially constant concentrations of the actives in the animal's bloodstream. The feeds may be produced by extrusion with addition of minor quantities of one or more actives so as to uniformly distribute the actives throughout the extruded product.

Abstract: An antifungal composition for the treatment of fungal infections in, around and under human nails, the composition comprising an aqueous solution of a wetting agent such as alcohol and a source of fluoride ions sufficient to establish a pH ranging from about 2.8 to about 3.5 in the composition. A preferred source of fluoride ions is stannous fluoride or stannous fluoride in an amount sufficient to saturate the solution. According to the method of the invention, one or more drops of the subject solution are topically applied to the infected nail and surrounding cuticular area periodically until the infection abates.

Abstract: A pharmaceutical dosage form such as a capsule capable of delivering therapeutic agents into the body in a time-controlled or position-controlled pulsatile release fashion, is composed of a multitude of multicoated particulates (beads, pellets, granules, etc.) made of one or more populations of beads. Each of these beads except an immediate release bead has at least two coated membrane barriers. One of the membrane barriers is composed of an enteric polymer while the second membrane barrier is composed of a mixture of water insoluble polymer and an enteric polymer. The composition and the thickness of the polymeric membrane barriers determine the lag time and duration of drug release from each of the bead populations. Optionally, an organic acid containing intermediate membrane may be applied for further modifying the lag time and/or the duration of drug release.

Abstract: Sheet-type packs which exert a skin cleaning effect while maintaining an effect of appropriately moistening the skin and are excellent in the feel in using and safety to the skin. In particular, sheet-type packs containing fruit extracts.

Abstract: Process for encapsulation of an uncharged crystalline solid particle include treating the crystalline solid particle material with amphiphilic substances and subsequently coating the material with a layer of charged polyelectrolyte or coating the material with a multilayer comprising alternating layers of oppositely charged polyelectrolytes.

Abstract: A transdermal contraceptive delivery system (TCDS) for fertility control in women is described. It comprises a backing layer, an adjoining layer of a solid absorption adhesive polymer matrix in which effective daily doses of an estrogen and a progestin are dispersed and released for transdermal absorption. Presently preferred is the use of the synthetic estrogen, ethinyl estradiol, and the synthetic progestin, levonorgestrel. Along with these two steroidal contraceptive agents, a combination of several chemical skin permeation enhancing agents, including capric acid, blended at specific weight ratios, ranging from 2:1:1:0.8 to 6:1:1:0.8, are homogeneously dispersed in the adhesive polymer matrix. The invention also provides a method of fertility control utilizing the transdermal contraceptive delivery system.

Abstract: To provide a swallowing-assistive drink for medicines that improves swallowing various medicines, is convenient and substitutable with ordinary drinking water, and does not disturb the efficacy of medicines and a swallowing method. A swallowing-assistive drink for helping swallowing medicines that contains water and an adhesive paste, forming a viscous liquid or a gelatinoid. If the drink is viscous liquid, the viscosity is 1,000-25,000 cP at 20° C., and if the drink is gelatinous, jelly gel strength is 10-100 g/cm2 at 20° C.